Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Aug;36(8):1677–1681. doi: 10.1128/aac.36.8.1677

Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: a 3-year survey in France.

D L Sirot 1, F W Goldstein 1, C J Soussy 1, A L Courtieu 1, M O Husson 1, J Lemozy 1, M Meyran 1, C Morel 1, R Perez 1, C Quentin-Noury 1, et al.
PMCID: PMC192029  PMID: 1416850

Abstract

During the second quarter each of 1988, 1989, and 1990, a French collaborative study group, including 12 university hospital laboratories, surveyed the resistance to beta-lactams of clinical isolates from hospitalized patients: consecutively, 10,641, 10,692, and 9,382 isolates were tested. The distribution of bacterial species over time was similar in each laboratory. The susceptibilities of microorganisms to amoxicillin, ticarcillin, cephalothin, cefoxitin, cefotaxime (CTX), ceftazidime (CAZ), aztreonam (ATM), and imipenem (IPM) were measured by the disk diffusion method in accordance with the recommendations of the Antibiogram Committee of the French Society for Microbiology. Five reference strains were included for quality control. Extended-spectrum beta-lactamases were detected by the synergistic effect of the combination of clavulanic acid-amoxicillin with CTX, CAZ, and ATM in the double-diffusion test. A synergistic effect with CTX, CAZ, and ATM was detected for 1.5% of all strains, mainly those of Klebsiella pneumoniae (13.3%). For this species, the synergy test enabled the detection of roughly 50% of the resistant strains misclassified as susceptible on the basis of interpretative standards. Extended-spectrum beta-lactamases disseminated in 1990 in most enterobacterial species but at a low frequency. Important variations in the percentages of resistant strains were observed in terms of bacterial species, hospitals, and wards. However, when the total number of strains was considered, the percentages of resistance to newer beta-lactams remained low.

Full text

PDF
1677

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brun-Buisson C., Legrand P., Philippon A., Montravers F., Ansquer M., Duval J. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet. 1987 Aug 8;2(8554):302–306. doi: 10.1016/s0140-6736(87)90891-9. [DOI] [PubMed] [Google Scholar]
  2. Brun-Buisson C., Legrand P., Rauss A., Richard C., Montravers F., Besbes M., Meakins J. L., Soussy C. J., Lemaire F. Intestinal decontamination for control of nosocomial multiresistant gram-negative bacilli. Study of an outbreak in an intensive care unit. Ann Intern Med. 1989 Jun 1;110(11):873–881. doi: 10.7326/0003-4819-110-11-873. [DOI] [PubMed] [Google Scholar]
  3. De Champs C., Rouby D., Guelon D., Sirot J., Sirot D., Beytout D., Gourgand J. M. A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase. J Hosp Infect. 1991 May;18(1):5–13. doi: 10.1016/0195-6701(91)90088-p. [DOI] [PubMed] [Google Scholar]
  4. Gootz T. D., Jackson D. B., Sherris J. C. Development of resistance to cephalosporins in clinical strains of Citrobacter spp. Antimicrob Agents Chemother. 1984 May;25(5):591–595. doi: 10.1128/aac.25.5.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Goulon M., Gajdos P., Pilliot J. Traitement des septicémies à bacilles à Gram négatif par le céfotaxime. 16 observations. Nouv Presse Med. 1981 Feb 26;10(8):613–616. [PubMed] [Google Scholar]
  6. Heizmann W. R. SDD and the novel extended-broad-spectrum beta-lactamases. J Antimicrob Chemother. 1990 Aug;26(2):295–296. doi: 10.1093/jac/26.2.295. [DOI] [PubMed] [Google Scholar]
  7. Jacoby G. A., Sutton L. Properties of plasmids responsible for production of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991 Jan;35(1):164–169. doi: 10.1128/aac.35.1.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jarlier V., Nicolas M. H., Fournier G., Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988 Jul-Aug;10(4):867–878. doi: 10.1093/clinids/10.4.867. [DOI] [PubMed] [Google Scholar]
  9. Kitzis M. D., Billot-Klein D., Goldstein F. W., Williamson R., Tran Van Nhieu G., Carlet J., Acar J. F., Gutmann L. Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors. Antimicrob Agents Chemother. 1988 Jan;32(1):9–14. doi: 10.1128/aac.32.1.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ledingham I. M., Alcock S. R., Eastaway A. T., McDonald J. C., McKay I. C., Ramsay G. Triple regimen of selective decontamination of the digestive tract, systemic cefotaxime, and microbiological surveillance for prevention of acquired infection in intensive care. Lancet. 1988 Apr 9;1(8589):785–790. doi: 10.1016/s0140-6736(88)91656-x. [DOI] [PubMed] [Google Scholar]
  11. Legrand P., Fournier G., Buré A., Jarlier V., Nicolas M. H., Decré D., Duval J., Philippon A. Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals. Eur J Clin Microbiol Infect Dis. 1989 Jun;8(6):527–529. doi: 10.1007/BF01967473. [DOI] [PubMed] [Google Scholar]
  12. Livermore D. M. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol. 1987 Aug;6(4):439–445. doi: 10.1007/BF02013107. [DOI] [PubMed] [Google Scholar]
  13. Nauciel C., Philippon A., Ronco E., Pilliot J., Guenounou M., Paul G., Brunel D., Outin H. D. Septicémies à Enterobacter cloacae et E. aerogenes: émergence de variants résistants (céphalosporinase déréprimée) en cours de traitement par des céphalosporines de troisième génération. Presse Med. 1985 Mar 23;14(12):673–676. [PubMed] [Google Scholar]
  14. Philippon A., Ben Redjeb S., Fournier G., Ben Hassen A. Epidemiology of extended spectrum beta-lactamases. Infection. 1989 Sep-Oct;17(5):347–354. doi: 10.1007/BF01650727. [DOI] [PubMed] [Google Scholar]
  15. Philippon A., Paul G., Vedel G., Nevot P. Résistance plasmidique aux céphalosporines de 3e génération. Presse Med. 1988 Oct 26;17(37):1883–1889. [PubMed] [Google Scholar]
  16. Sanders C. C. Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics. Annu Rev Microbiol. 1987;41:573–593. doi: 10.1146/annurev.mi.41.100187.003041. [DOI] [PubMed] [Google Scholar]
  17. Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]
  18. Seeberg A. H., Tolxdorff-Neutzling R. M., Wiedemann B. Chromosomal beta-lactamases of Enterobacter cloacae are responsible for resistance to third-generation cephalosporins. Antimicrob Agents Chemother. 1983 Jun;23(6):918–925. doi: 10.1128/aac.23.6.918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sirot D., Sirot J., Labia R., Morand A., Courvalin P., Darfeuille-Michaud A., Perroux R., Cluzel R. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase. J Antimicrob Chemother. 1987 Sep;20(3):323–334. doi: 10.1093/jac/20.3.323. [DOI] [PubMed] [Google Scholar]
  20. Sirot J., Chanal C., Petit A., Sirot D., Labia R., Gerbaud G. Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies. Rev Infect Dis. 1988 Jul-Aug;10(4):850–859. doi: 10.1093/clinids/10.4.850. [DOI] [PubMed] [Google Scholar]
  21. Smith C. E., Tillman B. S., Howell A. W., Longfield R. N., Jorgensen J. H. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother. 1990 Jun;34(6):1290–1293. doi: 10.1128/aac.34.6.1290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Vuthien H., Rolland M. Citrobacter freundii: émergence in vivo d'un mutant résistant aux bêta-lactamines au cours d'un traitement par la ceftazidime. Presse Med. 1986 Jun 28;15(26):1241–1242. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES